BioCryst Pharmaceuticals heads into Q3 with a contradictory setup: short sellers are pressing harder into a stock down 16% over the past month, while options traders are positioned for upside at their most aggressive in over a year.
Short interest has climbed to 16.7% of the free float, up roughly 13.5% over the past 30 days and 3.7% just this week alone. That puts BCRX in genuinely high-conviction short territory. Around 35.1 million shares are estimated short, close to the FINRA fortnightly settlement figure of 34.9 million as of mid-September. Yet the borrow market sends a conflicting signal. Availability is extremely loose at 684%, meaning roughly seven shares are available to borrow for every one already lent out, well above the 52-week tightest level of 289%. Cost to borrow has drifted to just 0.55%, barely off its 30-day low and a fraction of what a crowded short typically costs. The lending market is not under any stress, shorts can add positions cheaply and freely. The ORTEX short score has nudged higher to 63.6 from 61.8 a week ago, a steady but unspectacular build.
Options positioning tells the opposite story. Call demand has accelerated sharply, pushing the put/call ratio to 0.127, its lowest level in the past year and nearly 1.6 standard deviations below the 20-day average of 0.147. For context, the 52-week low on the PCR is 0.098 and the high was 0.315. The current reading reflects heavy call-side positioning, investors using options are leaning bullish at a moment when short sellers are leaning bearish. That divergence between two camps running in opposite directions is the defining tension of this week's setup.
The Street is similarly split. JP Morgan's Jessica Fye raised her price target from $12 to $13 this week while holding a Neutral rating, the second modest upward nudge from JPM in three months. RBC Capital is the more important recent move in the other direction: analyst Brian Abrahams downgraded BCRX on September 10 from Outperform to Sector Perform, cutting his target from $13 to $11. That downgrade follows an earlier August trim from $14 to $13. The consensus mean target is $20.73, though that figure is skewed by outlier bulls such as HC Wainwright, which holds a $32 target, and Cantor Fitzgerald at $29, both from mid-year. The broader analyst picture has bulls pointing to Orladeyo's continued commercial momentum, 2Q26 revenue of $158 million (up 10% year-on-year), and the deucrictibant XR prophylaxis NDA filing planned for the first half of 2027. Bears counter with Orladeyo's slowing growth curve, near-term competitive pressure from Pharvaris's Phase 3 prophylaxis data due in the current quarter, and navenibart's launch now expected no earlier than late 2028. EPS momentum factor scores are a relative bright spot: the 90-day reading ranks in the 93rd percentile, and the company has a solid earnings surprise track record at the 78th percentile. The short score factor, at the 20th percentile, reflects the above-average short positioning.
Institutional ownership adds texture to the bull side. BlackRock added roughly 1.2 million shares through August, bringing its position to 23.9 million shares, or 9.4% of shares outstanding. State Street built its stake by nearly 3 million shares over the same period and now holds 15.2 million, or 6.0%. Janus Henderson added 1.1 million shares. No Schedule 13D activist holds a position, all major holders are passive 13G filers. Stakes are as last disclosed and positions may have moved since.
After the most recent earnings print on August 5, BCRX gained 3.1% on the day and 17.4% over the following five trading days. That reaction is worth noting with the next results event now scheduled for November 5, 36 days away. The stock is currently trading at $8.27, down 5.8% on the week, against a backdrop of broad biotech weakness. Correlated peers KYTX and PRME fell 8.9% and 12.7% respectively on the week, while RIGL was roughly flat. The sector-wide selling creates the context for BCRX's slide, though the short build is outpacing what peer weakness alone would explain.
The watch list into November is clear: whether competitive HAE data from Pharvaris materialises in Q3 and how the Street reads it, and whether Orladeyo's quarterly revenue trajectory convinces doubters that growth has not stalled.
See the live data behind this article on ORTEX.
Open BCRX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
